share_log

Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference

Futu News ·  Aug 13 07:55  · Conference Call

The following is a summary of the Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript:

Financial Performance:

  • Pulse Biosciences reported cash and cash equivalents totaling $26.2 million as of June 30, 2024, compared to $58.7 million the previous year.

  • The company noted a total GAAP cost increase of $1.5 million to $11.7 million for Q2 2024, primarily driven by non-cash stock-based compensation.

  • Received $60 million in gross proceeds from a rights offering which closed in July 2024, not included in the reported cash balance.

Business Progress:

  • Completed first US soft tissue ablation cases under FDA clearance and received breakthrough device designation for a cardiac surgical system.

  • Expanded leadership team and moved headquarters to Miami, Florida.

  • Plans to initiate pivotal clinical trials for soft tissue ablation and a surgical system for atrial fibrillation in early 2025.

More details: Pulse Biosciences IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment